20 Dec 2021 argenx announces U.S. Food and Drug Administration (FDA) approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis Member news
16 Nov 2021 New study demonstrates Idylla™ EGFR Mutation Test (CE-IVD) shortens time to patient management decisions for patients with non-small cell lung cancer Member news
15 Nov 2021 Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis Member news
06 Oct 2021 Precirix dosed first patients in Phase I/II clinical study evaluating CAM-H2 in HER2-positive metastatic cancer Member news
04 Oct 2021 Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease Member news
04 Oct 2021 Sequana Medical announces FDA approval to expand patient enrolment in North American pivotal alfapump® study (POSEIDON) Member news
01 Sep 2021 ExeVir announces first patient enrolled in phase 1b/2 clinical study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19 Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
